β-Blockers for the Treatment of Misophonia and Misokinesia

Clin Neuropharmacol. 2022 Jan-Feb;45(1):13-14. doi: 10.1097/WNF.0000000000000492.

Abstract

Misophonia is an adverse physical and emotional reaction to certain repetitive trigger sounds, usually generated by other people. Misokinesia refers to visual triggers that are sometimes (but not always) related to trigger sounds. Despite how common and disabling these conditions can be, medication treatment of misophonia and misokinesia is largely unexplored. We present the first case of using a β-blocker (propranolol) to successfully treat a patient experiencing misophonia and misokinesia. A moderate dose (60 mg) of propranolol completely eliminated multiple auditory and visual trigger symptoms related to other people eating. His trigger response symptoms included overwhelming negative emotions and prominent sympathetic overactivity (fight-or-flight response). These symptoms were so severe that he had avoided most meals with friends and family for the past several years. Propranolol eliminated the emotional and physiological effects of both the auditory and visual triggers, with an Amsterdam Misophonia Scale score reduction from 15 to 2. This enabled him to resume eating meals with family and friends with no distress. The medication was well tolerated. In summary, we report the novel finding that β-blockers were markedly effective at treating the physical and emotional symptoms of a patient with misophonia and misokinesia. This suggests a novel treatment approach for these conditions.

Publication types

  • Case Reports

MeSH terms

  • Adrenergic beta-Antagonists* / therapeutic use
  • Humans
  • Hyperacusis* / drug therapy
  • Male
  • Phobic Disorders* / drug therapy

Substances

  • Adrenergic beta-Antagonists

Supplementary concepts

  • misophonia